Document is current
Any future updates will be listed below
-
Authors
Beer Wells, Eloise S.
De Conti, Laura
Kim, Hyung Chul
Rohani, Narjes
Chundru, Kartik
Svrzikapa, Nenad
McClorey, Graham
Watts, Laura M.
Dawes, Ruebena
Chen, Yuyang
Martin-Geary, Alexandra C.
Griffiths, Michael J.
Scott, Sam
Bamford, Rosemary A.
Wood, Matthew J.
Roberts, Thomas C.
Mill, Jonathan
Wright, Caroline F.
Baralle, Marco
Sanders, Stephan J.
Whiffin, Nicola
- License Information
-
More Information
Article History
Received: 27 January 2026
Accepted: 10 September 2026
First Online: 19 September 2026
Declarations
Competing interests: T.C.R and M.J.A.W. are inventors on patents related to uORF targeting technologies, and have filed a patent describing skipping of upstream exons for the removal of uORFs for protein upregulation. This IP is licensed to Orfonyx Bio Ltd, a biotechnology spin-out company that aims to develop uORF-targeting therapeutics. T.C.R., M.J.A.W., and N.S., are founders and shareholders in Orfonyx Bio. N.S. and G.M.C. are employees of Orfonyx Bio. T.C.R. and M.J.A.W. are consultants for Orfonyx Bio. S.J.S has acted as a paid consultant for Orfonyx Bio. N.W., and S.J.S., receive research funding from BioMarin Pharmaceutical. The remaining authors declare that they have no competing interests.
